Mirion Taps New Leaders for Nuclear, Medicine, and AI Push

ATLANTA, GA – February 11, 2026 – Mirion, a global leader in radiation technology, has announced a significant strategic realignment of its leadership team, appointing three executives to newly created or elevated roles. The move signals a concerted effort to deepen its focus on the evolving nuclear power landscape, expand its footprint in advanced cancer care, and embed artificial intelligence across its enterprise.

The appointments include Tighe Smith as the company's first Chief Nuclear Officer, Shelia Webb as President of Nuclear Medicine, and Shahmeer Mirza as the inaugural Chief Artificial Intelligence & Digital Officer. The simultaneous creation and staffing of these high-level positions underscore a comprehensive strategy to fortify Mirion’s market leadership and accelerate growth in its core, highly regulated sectors.

A Strategic Trifecta for Future Growth

These leadership changes come as Mirion builds on a period of substantial momentum. The company recently reported a landmark year, securing over $1 billion in orders and returning to profitability with a net income of $29.8 million in 2025. This financial strength has been bolstered by strategic acquisitions, including the purchases of nuclear regulatory specialist Certrec and project developer Paragon Energy Solutions. These moves have significantly increased Mirion's exposure to the nuclear power sector, which now accounts for approximately 40% of its total revenue.

Mirion Chairman and Chief Executive Officer Thomas Logan framed the appointments as a direct extension of this strategy. “Tighe’s technical expertise and understanding of the global nuclear landscape make him exceptionally well suited for this new role,” Logan said, emphasizing the need for focused leadership as the nuclear field evolves. The new structure appears designed to leverage this growth, dedicating top-tier talent to capitalize on emerging opportunities in next-generation reactors, digital health, and enterprise-wide operational efficiency.

Powering the Next Nuclear Renaissance

The promotion of Tighe Smith to Chief Nuclear Officer is a clear bet on the future of nuclear energy. Smith, who previously held the same title at the recently acquired Paragon Energy Solutions, is tasked with leading Mirion's global strategy for both the existing reactor fleet and the burgeoning market for advanced and small modular reactors (SMRs).

This market is poised for significant expansion, driven by global decarbonization goals and the need for reliable, carbon-free power to support energy-intensive technologies like AI data centers. Market projections estimate the global SMR market could grow from around $6 billion in 2025 to over $8.7 billion by 2034. However, the path to deployment is fraught with challenges, including complex regulatory hurdles, high initial financing costs, and the need for a robust supply chain.

Smith's deep background, which includes over 20 years in nuclear engineering and leadership roles at the American Nuclear Society and the International Electrotechnical Commission (IEC), positions him to navigate this complex terrain. “As the nuclear field evolves and new reactor technologies move forward, his leadership will be essential in ensuring Mirion continues to meet the needs of our customers and partners,” Logan stated. Smith’s role will be critical in aligning Mirion’s portfolio of radiation detection, monitoring, and safety systems with the specific demands of next-generation reactor designs.

A Digital Prescription for Cancer Care

While fortifying its nuclear power division, Mirion is also making a dedicated push into nuclear medicine. Shelia Webb’s appointment as President of Nuclear Medicine places a seasoned internal leader at the helm of a rapidly innovating sector. The global nuclear medicine market, valued at over $16 billion, is experiencing explosive growth, fueled by advancements in theranostics—an approach that combines diagnostic imaging with targeted radionuclide therapy to treat cancers with high precision.

Webb is tasked with leading the strategic development of the business unit, with a particular focus on integrating the ec2 Software and Capintec brands to support advanced cancer care. Her transition from her previous role as Mirion’s Chief Digital Officer is telling. It highlights the company's strategy of leveraging digital innovation to drive progress in its medical division. Webb was instrumental in integrating ec2 Software after its 2023 acquisition and has a long history with the company, including roles as Chief Technology Officer and President of the Spectroscopy Division.

“Shelia’s extensive experience in leading Mirion’s digital initiatives and her successful management of ec2 have equipped her with unique insights and a proven track record that will benefit the Nuclear Medicine business moving forward,” Logan commented. Her leadership is expected to accelerate the development of integrated, software-driven solutions that enhance quality assurance and streamline complex workflows in oncology.

Embedding Intelligence: The AI Imperative

Perhaps the most forward-looking move is the appointment of Shahmeer Mirza as Mirion’s first Chief Artificial Intelligence & Digital Officer. This role was created to accelerate the adoption of AI and machine learning, not just in products, but as a core enabler of internal operations, from manufacturing and supply chain to R&D.

Mirza, who holds over 130 patents and previously led enterprise data and AI strategies at 7-Eleven, is charged with a dual mandate: drive innovation and enforce discipline. In highly regulated industries like nuclear and medical, the adoption of AI carries unique challenges related to safety, security, and regulatory compliance. A key part of Mirza’s role will be implementing governance frameworks for the “ethical, secure, transparent, and compliant AI use.”

This focus on responsible AI is critical for building trust with regulators and customers. Mirza will lead the integration of advanced analytics to optimize performance while ensuring that the “black box” nature of some AI models does not compromise the high standards of verification and validation required in Mirion’s fields. “Creating this role reflects our focus on being a future-minded, data-driven organization,” Logan added. “Shahmeer’s leadership will help us improve how we operate and execute, delivering measurable value to our company and customers.”

With solutions already deployed in 98% of the world’s nuclear plants and over 6,000 cancer centers, Mirion's new leadership structure is designed to not only defend its current market position but to actively shape the future of safety and innovation in these critical global industries.